XENOTHERA

XENOTHERA is a clinical-stage biotechnology company at the forefront of innovation, creating new therapeutic paradigms across multiple fields. XENOTHERA’s patented technology platform is built on dual expertise in immunology and genetic engineering. It has pioneered an innovative approach to immunotherapy through the development of glycosylated humanized polyclonal antibodies (GH-pAb). XENOTHERA’s antibodies are meticulously designed to exhibit high therapeutic efficacy. In less than five years, XENOTHERA has advanced its first product, LIS1, into clinical trials. LIS1 represents a novel induction therapy for solid organ transplantation, targeting a billion-dollar market.